Rights and permissions
About this article
Cite this article
Tolterodine less costly than oxybutynin in overactive bladder. Pharmacoecon. Outcomes News 388, 8 (2002). https://doi.org/10.1007/BF03279844
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03279844